|
T8730 |
BMS986260
|
|
TGF-beta/Smad
|
|
BMS-986260 is a selective, and orally bioavailable TGFβR1 inhibitor(IC50 = 1.6 nM). |
|
T69851 |
Riminkefon
|
|
|
|
Riminkefon is a kappa opioid receptor agonist . |
|
T0860L |
Mefloquine
|
Ro215998,WR 142490,Ro-215998,Lariam,Ro 215998 |
Others
|
|
Mefloquine (Ro 215998), a quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine is also a K+ channel (KvQT1/minK) antagonist with an IC50 of ~1 μM. Mefloquine can be used for malaria, systemic l... |
|
T0860 |
Mefloquine hydrochloride
|
Mefloquin hydrochloride,Mefloquine HCl |
Potassium Channel
,
SARS-CoV
,
Reactive Oxygen Species
,
Parasite
,
Autophagy
|
|
Mefloquine hydrochloride (Mefloquin hydrochloride) is a quinoline derivative used for the prevention and therapy of P. falciparum malaria. |
|
T33945 |
PF-06260933 HCl
|
PF06260933 dihydrochloride,PF-06260933 dihydrochloride,PF 06260933 dihydrochloride |
|
|
PF-06260933 Dihydrochloride is a MAP4K4 (HGK) inhibitor (IC50 = 140 nM). It can improve the fasting hyperglycemia in mice. In addition, it inhibited Mink and Tnik (IC50 values of 8 and 13 nM, respectively). |
|
T36016 |
PF 06260933 dihydrochloride
|
|
|
|
MAP4K4 (HGK) inhibitor (IC50 = 140 nM). Also inhibits MINK and TNIK (IC50 values are 8 and 13 nM, respectively). Improves fasting hyperglycemia in mice. Orally active.
Ammirati et al (2015) Discovery of an in vivo tool t... |
